Zealand Pharma Nachrichten

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• 
  Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026) (öffnet in neuem Tab)

  GlobeNewswire · 05.10.2026

• 
  Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts (öffnet in neuem Tab)

  01.10.2026

• Zealand Pharma Reports 13.1% Weight Loss in Phase 3 Survodutide Trial (öffnet in neuem Tab)

  MT Newswires · 01.10.2026

• 
  Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes (öffnet in neuem Tab)

  GlobeNewswire · 01.10.2026

• 
  Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 (öffnet in neuem Tab)

  GlobeNewswire · 30.09.2026

• 
  Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology (öffnet in neuem Tab)

  GlobeNewswire · 29.09.2026

• 
  Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) (öffnet in neuem Tab)

  GlobeNewswire · 28.09.2026

• 
  Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity (öffnet in neuem Tab)

  GlobeNewswire · 22.09.2026

• 
  Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) (öffnet in neuem Tab)

  GlobeNewswire · 21.09.2026

• 
  Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome (öffnet in neuem Tab)

  GlobeNewswire · 18.09.2026

• 
  Zealand Pharma (CPSE:ZEAL) Grants Exclusive Type 1 Diabetes Peptide License (öffnet in neuem Tab)

  Simply Wall St. · 18.09.2026

• Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes (öffnet in neuem Tab)

  15.09.2026

• 
  Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) (öffnet in neuem Tab)

  GlobeNewswire · 14.09.2026

• 
  Zealand Pharma increases its share capital as a result of the exercise of employee warrants (öffnet in neuem Tab)

  GlobeNewswire · 10.09.2026

• Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference (öffnet in neuem Tab)

  09.09.2026

• Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) (öffnet in neuem Tab)

  07.09.2026

• Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) (öffnet in neuem Tab)

  02.09.2026

• Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough (öffnet in neuem Tab)

  01.09.2026

• Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) (öffnet in neuem Tab)

  31.08.2026

• Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (öffnet in neuem Tab)

  28.08.2026